Hidemasa et al. recruited pediatric patients with MLL-rearranged (MLL-r) AML (n = 56) alongside data from the TARGET study’s pediatric cohorts with MLL-r AML (n = 104), non–MLL-r AML (n = 581), and adult MLL-r AML (n = 81) into their study, and they found that KRAS mutations were most frequent in pediatric patients with high-risk MLL fusions (MLL-MLLLT10, MLL-MLLT4, and MLL-MLLT1), accounting for 26.25% (42/160) in MLL-r AML. This evidence concerns the gene KMT2A and acute myeloid leukemia.